Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRNA 4157 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Colon cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms KEYNOTE-603
  • Sponsors Moderna Therapeutics

    • Most Recent Events

    • 10 Apr 2024 Results (n=28) assessing safety and efficacy of INT+ pembrolizumab in advanced unresectable HPV- head & neck carcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 04 Jan 2024 Planned number of patients changed from 143 to 242.
    • 04 Jan 2024 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top